Developer docs
API playgroundTry for free, no card

Search company profiles

The Emmes Group

Full company profile

uuid00k5su1

Namestring
The Emmes Group
Legal namestring
The Emmes Company, LLC
Company typeenum
Private
Founded yearint
1977
Descriptiontext

The Emmes Group is a privately held, US-based contract research organization (CRO) founded in 1977 and headquartered in Rockville, Maryland. Operating as the self-described "first specialty, tech and AI-based CRO," it delivers Phase I–IV clinical research services to US government agencies, public-private partnerships, and commercial biopharmaceutical companies across 90+ countries, with 32,000+ trial sites managed and 2,150+ trials conducted to date. The company is organized into two core operating units: Emmes (the CRO services arm) and Veridix (the technology and AI platform), with additional specialty sub-brands VaxTrials (vaccines/infectious disease) and OptymEdge (ophthalmology).

The Emmes CRO arm provides full-service clinical capabilities including biostatistics, clinical data management, clinical trial management, global regulatory affairs, pharmacovigilance, and medical monitoring, with deep specialization in vaccines and infectious diseases, ophthalmology, clinical neuroscience, rare disease, cell and gene therapy, government programs, hematology, oncology, maternal and child health, and medical devices. The Veridix platform layers proprietary technology on top of these services, including the Veridix eClinical Platform (EDC, RTSM, eCOA/ePRO, decentralized clinical trials, and a Health Navigator module), GlobalTrace for site and supply chain tracking, and a suite of named AI Agents — Biostats and Analysis Agent, Data Management Agent, Document Authoring Agent — and VERA, an AI Reporting Agent for clinical analytics. In July 2024, Emmes acquired Clinical Entity Modeling tools from health tech startup Miimansa AI as part of a multi-year strategic partnership, adding AI-powered structured entity modeling to its technology stack.

Emmes generates revenue through project-based CRO contracts awarded via a Request for Proposal (RFP) process, supplemented by what source data characterizes as recurring/subscription-style engagement. Customers include US Government Agencies, Public-Private Partnerships, and Commercial Biopharma Companies across primary verticals of Government Health Agencies and Biopharmaceutical Companies (with Specialty Biopharma as a secondary vertical). Pricing is quote-based and not publicly disclosed. The company is ISO-certified and reports 434+ peer-reviewed publications since 2016, supporting its positioning as a scientifically rigorous, government-trusted research partner now actively expanding its commercial biopharma footprint under recently appointed commercial leadership.

Short descriptiontext

The Emmes Group is a privately held specialty CRO founded in 1977 in Rockville, MD, combining full-service clinical research with the Veridix AI-enabled eClinical platform. It serves US government agencies, public-private partnerships, and commercial biopharma clients across 90+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersRockville, United States
HQ citystring
Rockville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
clinical research services, contract research organization, clinical trial management, eClinical platform, biostatistics services
Industry6 codes
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs
SECONDARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs
SECONDARYHLAGAAAG
Medical Writing & Regulatory Submission Support CROs
SECONDARYHLACAOAB
eCOA/ePRO/eDiary & Patient-Facing Data Collection
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Health Services8000
Product category
Clinical Research Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1CRO Services
TypeSubscription Recurring
Description

Emmes Group generates revenue primarily through providing Contract Research Organization (CRO) services including clinical trial management, biostatistics, data management, regulatory affairs, and pharmacovigilance. As a specialty CRO with global operations across 90+ countries, revenue is generated through project-based contracts with biopharma companies, government agencies, and public-private partnerships.

theemmesgroup.com:443
Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1Emmes
Description

CRO (Contract Research Organization) providing clinical research services across multiple therapeutic areas including vaccines, ophthalmology, neuroscience, rare disease, cell & gene therapy, government, hematology, oncology, and medical devices.

theemmesgroup.com:443
+3 more records
Core offering1 text field

The Emmes Group is a full-service Contract Research Organization (CRO) delivering Phase I–IV clinical trial management across 90+ countries, supported by a proprietary AI-enabled technology platform (Veridix) that provides electronic data capture, randomization and supply management, eCOA/ePRO, decentralized clinical trials, global site tracking, and AI agents for biostatistics, data management, and document authoring. Specialty therapeutic expertise is delivered through dedicated brands for vaccines/infectious disease, ophthalmology, clinical neuroscience, rare disease, cell & gene therapy, and government health programs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Reduced costs and time for clinical trials through AI-enabled automation of data processing
Product overview1 text field

The Emmes Group operates as the industry's first specialty, tech and AI-based CRO with a platform-plus-modules architecture. The core offering consists of Emmes CRO providing full-service clinical research across multiple therapeutic specialties, supported by the Veridix eClinical Platform delivering technology solutions including EDC, RTSM, eCOA/ePRO, and Decentralized Clinical Trials. AI capabilities are embedded through Veridix AI Agents (Biostats and Analysis Agent, Data Management Agent, Document Authoring Agent) and VERA reporting. Specialty sub-brands include VaxTrials for vaccines and OptymEdge for ophthalmology. The company reports 2,150+ Phase I-IV trials conducted in 90+ countries across 32,000+ clinical trial sites.

Product and service4 records
1Emmes CRO Clinical Research Services
CategoryCRO Clinical Research Services
Description

Full-service Contract Research Organization delivering Phase I–IV clinical trial management, biostatistics, clinical data management, global regulatory affairs, pharmacovigilance, and medical monitoring across 90+ countries with specialty expertise in vaccines, ophthalmology, neuroscience, rare disease, cell & gene therapy, oncology, hematology, maternal & child health, and medical devices.

2Veridix eClinical Platform
CategoryClinical Trial Technology Platform
Description

Proprietary technology and AI-enabled eClinical platform providing electronic data capture (EDC), randomization and trial supply management (RTSM), electronic clinical outcome assessments (eCOA/ePRO), decentralized clinical trials (DCT), Health Navigator for patient engagement, GlobalTrace for site and supply tracking, AI agents for biostatistics, data management, and document authoring, and VERA analytics and reporting for clinical trial execution by sponsors and CRO teams.

3VaxTrials
CategoryCRO Specialty Brand
Description

Specialty CRO brand dedicated to designing and running vaccine and infectious disease clinical trials for government agencies, public-private partnerships, and commercial biopharma sponsors.

4OptymEdge
CategoryCRO Specialty Brand
Description

Specialty CRO brand dedicated to ophthalmology clinical trials, supporting sponsors with design, site management, and clinical execution for vision-related therapies.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-24
Description

Multi-year strategic partnership with health tech startup Miimansa AI, including acquisition of Clinical Entity Modeling tools. Collaboration aims to leverage advanced AI techniques to accelerate and automate data processing in clinical trials, potentially reducing costs and time. This partnership strengthens Emmes Group's AI capabilities and positions them at the forefront of AI-enabled clinical research.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large biopharma-focused CRO (now PE-owned) offering clinical development and commercial services. Comparable on biopharma customer overlap and Phase II–IV positioning.

TypeDirect peer
Description

Technology-led clinical trial endpoint and eCOA/ePRO specialist offering software and scientific expertise for decentralized and hybrid trials. Highly comparable to Emmes's Veridix platform on eClinical and patient-facing data capture.

TypeEmerging player
Description

Mid-sized specialty CRO with particular strength in cell and gene therapy and rare disease — directly mirroring Emmes's VaxTrials and rare disease specialty focus, though smaller in scale.

TypeDirect peer
Description

Privately held specialty CRO focused on complex therapeutic areas including rare disease, neuroscience, and oncology. Highly comparable to Emmes given similar mid-sized scale, specialty positioning, and private ownership structure.

TypeBroad incumbent
Description

Diversified CRO/CDMO spanning preclinical through clinical, with comparable specialty therapeutic focus and global footprint. Competes with Emmes for early-stage clinical and discovery-to-Phase II sponsor budgets.

TypeDirect peer
Description

Mid-sized, tech-forward full-service clinical CRO with strong organic growth model and proprietary technology stack. Closely comparable to Emmes in operating philosophy (specialty CRO with technology differentiation), though larger and publicly listed.

TypeBroad incumbent
Description

Large global CRO with strong specialty/biopharma focus and significant Phase I-IV capabilities. Comparable to Emmes on the biopharma customer base and therapeutic breadth, though materially larger and PE-owned (EQT/Goldman).

TypeBroad incumbent
Description

Clinical CRO spun out of Labcorp in 2023, offering full-service Phase I-IV development with strong technology and biopharma franchise. Direct competitor on mid- and large-sized clinical CRO bids.

TypeBroad incumbent
Description

Top-tier global CRO offering full-service clinical development including a strong technology and decentralized trial portfolio. Overlaps with Emmes on Phase I-IV biopharma services; Emmes's new CCO Germaine Gross is a former ICON BD leader.

TypeBroad incumbent
Description

Largest global CRO with deep technology, real-world evidence, and commercial capabilities. Sets the competitive benchmark Emmes must beat on bundled biopharma programs and AI/data infrastructure investment.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

The Emmes Group

Clinical Research Servicestheemmesgroup.com

The Emmes Group is a privately held specialty CRO founded in 1977 in Rockville, MD, combining full-service clinical research with the Veridix AI-enabled eClinical platform. It serves US government agencies, public-private partnerships, and commercial biopharma clients across 90+ countries.

What The Emmes Group does

The Emmes Group is a privately held, US-based contract research organization (CRO) founded in 1977 and headquartered in Rockville, Maryland. Operating as the self-described "first specialty, tech and AI-based CRO," it delivers Phase I–IV clinical research services to US government agencies, public-private partnerships, and commercial biopharmaceutical companies across 90+ countries, with 32,000+ trial sites managed and 2,150+ trials conducted to date. The company is organized into two core operating units: Emmes (the CRO services arm) and Veridix (the technology and AI platform), with additional specialty sub-brands VaxTrials (vaccines/infectious disease) and OptymEdge (ophthalmology).

The Emmes CRO arm provides full-service clinical capabilities including biostatistics, clinical data management, clinical trial management, global regulatory affairs, pharmacovigilance, and medical monitoring, with deep specialization in vaccines and infectious diseases, ophthalmology, clinical neuroscience, rare disease, cell and gene therapy, government programs, hematology, oncology, maternal and child health, and medical devices. The Veridix platform layers proprietary technology on top of these services, including the Veridix eClinical Platform (EDC, RTSM, eCOA/ePRO, decentralized clinical trials, and a Health Navigator module), GlobalTrace for site and supply chain tracking, and a suite of named AI Agents — Biostats and Analysis Agent, Data Management Agent, Document Authoring Agent — and VERA, an AI Reporting Agent for clinical analytics. In July 2024, Emmes acquired Clinical Entity Modeling tools from health tech startup Miimansa AI as part of a multi-year strategic partnership, adding AI-powered structured entity modeling to its technology stack.

Emmes generates revenue through project-based CRO contracts awarded via a Request for Proposal (RFP) process, supplemented by what source data characterizes as recurring/subscription-style engagement. Customers include US Government Agencies, Public-Private Partnerships, and Commercial Biopharma Companies across primary verticals of Government Health Agencies and Biopharmaceutical Companies (with Specialty Biopharma as a secondary vertical). Pricing is quote-based and not publicly disclosed. The company is ISO-certified and reports 434+ peer-reviewed publications since 2016, supporting its positioning as a scientifically rigorous, government-trusted research partner now actively expanding its commercial biopharma footprint under recently appointed commercial leadership.

The Emmes Group firmographics

Firmographics
Name
The Emmes Group
Legal name
The Emmes Company, LLC
Website
https://theemmesgroup.com
Company type
Private
Founded year
1977
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
The Emmes Group is a privately held specialty CRO founded in 1977 in Rockville, MD, combining full-service clinical research with the Veridix AI-enabled eClinical platform. It serves US government agencies, public-private partnerships, and commercial biopharma clients across 90+ countries.
Ownership category
akta.pro rank

The Emmes Group industry classification

Industry
Product category
Clinical Research Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs
SECONDARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs
SECONDARYHLAGAAAG
Medical Writing & Regulatory Submission Support CROs
SECONDARYHLACAOAB
eCOA/ePRO/eDiary & Patient-Facing Data Collection
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)

Keywords

  • Clinical research services
  • Contract research organization
  • Clinical trial management
  • EClinical platform
  • Biostatistics services

Where The Emmes Group is headquartered

Location

Headquarters

HQ city
Rockville
HQ country
United States
HQ region
North America

Markets served

The Emmes Group business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. CRO Services: Emmes Group generates revenue primarily through providing Contract Research Organization (CRO) services including clinical trial management, biostatistics, data management, regulatory affairs, and pharmacovigilance. As a specialty CRO with global operations across 90+ countries, revenue is generated through project-based contracts with biopharma companies, government agencies, and public-private partnerships.

Go-to-market motion1 record

The Emmes Group product offering

Product offering

Core offering

The Emmes Group is a full-service Contract Research Organization (CRO) delivering Phase I–IV clinical trial management across 90+ countries, supported by a proprietary AI-enabled technology platform (Veridix) that provides electronic data capture, randomization and supply management, eCOA/ePRO, decentralized clinical trials, global site tracking, and AI agents for biostatistics, data management, and document authoring. Specialty therapeutic expertise is delivered through dedicated brands for vaccines/infectious disease, ophthalmology, clinical neuroscience, rare disease, cell & gene therapy, and government health programs.

Product overview

The Emmes Group operates as the industry's first specialty, tech and AI-based CRO with a platform-plus-modules architecture. The core offering consists of Emmes CRO providing full-service clinical research across multiple therapeutic specialties, supported by the Veridix eClinical Platform delivering technology solutions including EDC, RTSM, eCOA/ePRO, and Decentralized Clinical Trials. AI capabilities are embedded through Veridix AI Agents (Biostats and Analysis Agent, Data Management Agent, Document Authoring Agent) and VERA reporting. Specialty sub-brands include VaxTrials for vaccines and OptymEdge for ophthalmology. The company reports 2,150+ Phase I-IV trials conducted in 90+ countries across 32,000+ clinical trial sites.

Differentiator

Problem solved

Functional benefit

Brands

  • Emmes: CRO (Contract Research Organization) providing clinical research services across multiple therapeutic areas including vaccines, ophthalmology, neuroscience, rare disease, cell & gene therapy, government, hematology, oncology, and medical devices.
  • Veridix
  • VaxTrials
  • OptymEdge

Products and services

  • Emmes CRO Clinical Research Services Full-service Contract Research Organization delivering Phase I–IV clinical trial management, biostatistics, clinical data management, global regulatory affairs, pharmacovigilance, and medical monitoring across 90+ countries with specialty expertise in vaccines, ophthalmology, neuroscience, rare disease, cell & gene therapy, oncology, hematology, maternal & child health, and medical devices.
  • Veridix eClinical Platform Proprietary technology and AI-enabled eClinical platform providing electronic data capture (EDC), randomization and trial supply management (RTSM), electronic clinical outcome assessments (eCOA/ePRO), decentralized clinical trials (DCT), Health Navigator for patient engagement, GlobalTrace for site and supply tracking, AI agents for biostatistics, data management, and document authoring, and VERA analytics and reporting for clinical trial execution by sponsors and CRO teams.
  • VaxTrials Specialty CRO brand dedicated to designing and running vaccine and infectious disease clinical trials for government agencies, public-private partnerships, and commercial biopharma sponsors.
  • OptymEdge Specialty CRO brand dedicated to ophthalmology clinical trials, supporting sponsors with design, site management, and clinical execution for vision-related therapies.

Quantifiable outcome

  • Reduced costs and time for clinical trials through AI-enabled automation of data processing

Companies that use The Emmes Group

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

The Emmes Group technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature6 records

The Emmes Group partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Miimansa AIcoreStrategic or Co-development Partner · 24 July 2024Multi-year strategic partnership with health tech startup Miimansa AI, including acquisition of Clinical Entity Modeling tools. Collaboration aims to leverage advanced AI techniques to accelerate and automate data processing in clinical trials, potentially reducing costs and time. This partnership strengthens Emmes Group's AI capabilities and positions them at the forefront of AI-enabled clinical research.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

The Emmes Group competitors and assessment

Company assessment

Broad incumbents

  • Syneos Health: Large biopharma-focused CRO (now PE-owned) offering clinical development and commercial services. Comparable on biopharma customer overlap and Phase II–IV positioning.
  • Charles River Laboratories: Diversified CRO/CDMO spanning preclinical through clinical, with comparable specialty therapeutic focus and global footprint. Competes with Emmes for early-stage clinical and discovery-to-Phase II sponsor budgets.
  • Parexel International: Large global CRO with strong specialty/biopharma focus and significant Phase I-IV capabilities. Comparable to Emmes on the biopharma customer base and therapeutic breadth, though materially larger and PE-owned (EQT/Goldman).
  • Fortrea: Clinical CRO spun out of Labcorp in 2023, offering full-service Phase I-IV development with strong technology and biopharma franchise. Direct competitor on mid- and large-sized clinical CRO bids.
  • ICON plc: Top-tier global CRO offering full-service clinical development including a strong technology and decentralized trial portfolio. Overlaps with Emmes on Phase I-IV biopharma services; Emmes's new CCO Germaine Gross is a former ICON BD leader.
  • IQVIA: Largest global CRO with deep technology, real-world evidence, and commercial capabilities. Sets the competitive benchmark Emmes must beat on bundled biopharma programs and AI/data infrastructure investment.

Direct peers

  • Clario: Technology-led clinical trial endpoint and eCOA/ePRO specialist offering software and scientific expertise for decentralized and hybrid trials. Highly comparable to Emmes's Veridix platform on eClinical and patient-facing data capture.
  • Worldwide Clinical Trials: Privately held specialty CRO focused on complex therapeutic areas including rare disease, neuroscience, and oncology. Highly comparable to Emmes given similar mid-sized scale, specialty positioning, and private ownership structure.
  • Medpace: Mid-sized, tech-forward full-service clinical CRO with strong organic growth model and proprietary technology stack. Closely comparable to Emmes in operating philosophy (specialty CRO with technology differentiation), though larger and publicly listed.

Emerging players

  • Allucent: Mid-sized specialty CRO with particular strength in cell and gene therapy and rare disease — directly mirroring Emmes's VaxTrials and rare disease specialty focus, though smaller in scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

The Emmes Group social profiles

Digital presence

The Emmes Group compliance and trust

Trust signal

Compliance1 record

The Emmes Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

The Emmes Group leadership team

Management profile

Number of profiles

Profiles2 records

The Emmes Group funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

The Emmes Group M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Emmes Group

What does The Emmes Group do?

The Emmes Group is a full-service Contract Research Organization (CRO) delivering Phase I–IV clinical trial management across 90+ countries, supported by a proprietary AI-enabled technology platform (Veridix) that provides electronic data capture, randomization and supply management, eCOA/ePRO, decentralized clinical trials, global site tracking, and AI agents for biostatistics, data management, and document authoring. Specialty therapeutic expertise is delivered through dedicated brands for vaccines/infectious disease, ophthalmology, clinical neuroscience, rare disease, cell & gene therapy, and government health programs.

Is The Emmes Group a public or private company?

The Emmes Group is a private company. It is classified as unknown and is currently operating.

When was The Emmes Group founded?

The Emmes Group was founded in 1977. It employs 1,001 to 5,000 people.

Where is The Emmes Group based?

The Emmes Group is headquartered in Rockville, United States, in the North America region.

How does The Emmes Group make money?

One revenue line is on record: CRO Services.

Who are The Emmes Group's main competitors?

Broad incumbents on record are Syneos Health, Charles River Laboratories, Parexel International, Fortrea, ICON plc and IQVIA. Direct peers are Clario, Worldwide Clinical Trials and Medpace. Allucent is listed as an emerging player.

Does The Emmes Group have an API?

No public API is recorded for The Emmes Group.

What industry is The Emmes Group in?

The Emmes Group's product category is Clinical Research Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAF, Clinical Data Management, Biostatistics & Statistical Programming CROs. Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceThe Emmes Group Appoints Dr. Rama Kondru as Chief Executive OfficerThe Emmes Group appointed Dr. Rama Kondru as CEO, effective immediately. He previously served as CEO of Veridix and brings 25 years of experience in clinical development technology. The appointment aims to combine Emmes' legacy with AI and technology to accelerate biomedical discovery.AijournThe Emmes Group Appoints Dr. Rama Kondru as Chief Executive OfficerThe Emmes Group appointed Dr. Rama Kondru as its new Chief Executive Officer, effective immediately. Dr. Kondru previously served as CEO of Veridix, an AI and technology business within The Emmes Group, bringing extensive experience from roles at Medidata Solutions and Johnson & Johnson. This leadership change aims to combine the company's scientific legacy with modern AI and technology to accelerate biomedical discovery and clinical trial efficiency.PR NewswireThe Emmes Group Appoints Dr. Rama Kondru as Chief Executive OfficerThe Emmes Group appointed Dr. Rama Kondru as its new Chief Executive Officer, effective immediately. Dr. Kondru previously served as CEO of Veridix, an AI and data sciences business within the company, bringing extensive experience from roles at Medidata Solutions and Johnson & Johnson. The appointment aims to leverage artificial intelligence and technology to accelerate clinical trials and biomedical discovery.citybizEmmes Group Appoints Germaine Gross as Chief Commercial OfficerEmmes Group announced the appointment of Germaine Gross as Chief Commercial Officer of Emmes Biopharma, a role in which she will report directly to CEO Sastry Chilukuri and serve on the Executive Management Committee. Gross brings over 30 years of life sciences experience and 15 years of CRO business development leadership, having previously held roles at ICON, PRA Health Sciences, and INC Research. The appointment is positioned as a strategic move to expand Emmes Biopharma's footprint and accelerate growth through AI-enabled clinical research solutions.PR NewswireEmmes Group® names Germaine Gross Chief Commercial Officer of Emmes® BiopharmaEmmes Group announced the appointment of Germaine Gross as Chief Commercial Officer of Emmes Biopharma, effective immediately. Gross brings over 30 years of life sciences experience and 15 years of CRO business development leadership, having previously led the Asia Pacific Commercial Team at ICON. The appointment is positioned as a strategic move to drive growth and expand Emmes Biopharma's footprint leveraging AI and advanced technology in clinical research.PR NewswireEmmes Group recognized as a top EDC platform by Everest GroupEmmes Group has been recognized as a "Major Contender" in Everest Group's Life Sciences Electronic Data Capture Products PEAK Matrix Assessment 2024 for its Advantage eClinical Cloud platform, marking the company's first inclusion in this assessment. The platform distinguished itself through its unified eClinical approach, AI-powered capabilities, and therapeutic area expertise, having supported over 1,200 clinical trials with more than 1.1 million patients across multiple countries and therapeutic areas. Veridix AI, the technology and AI division of Emmes Group, highlighted the platform's modern technology stack that streamlines data transformations and accelerates clinical insights for sponsors.PR NewswireVeridix AI, part of Emmes Group, Announces New Protocol Digitization CapabilitiesVeridix AI, part of Emmes Group, announced protocol digitization capabilities that use NLP and AI to extract structured data from clinical trial protocols. The approach automates database study builds, cutting timelines by up to 30%, and has been deployed in over 40 study builds. Future releases will add automated eCRF construction.PR NewswireEmmes Group kooperiert mit Miimansa AI, um den Einsatz von generativer KI in der klinischen Forschung zu beschleunigenDie Emmes Group, ein globales Auftragsforschungsinstitut mit Sitz in Maryland, gab am 23. Juli 2024 eine mehrjährige strategische Partnerschaft mit dem KI-Startup Miimansa AI bekannt. Im Rahmen der Partnerschaft erwirbt Emmes die Clinical Entity Modeling Tools von Miimansa, die auf Large Language Modeling und generativer KI basieren, um seine Veridix AI-Plattform und die Concord GenAI-Plattform zu erweitern. Ziel ist es, die Verarbeitung klinischer Daten zu beschleunigen und den Zeit- und Kostenaufwand manueller Datenverarbeitung in der klinischen Forschung zu reduzieren.PR NewswireEmmes Group se une a Miimansa AI para acelerar la adopción de la IA generativa en la investigación clínicaEmmes Group, a global technology-driven contract research organization (CRO), announced a multi-year strategic partnership with Miimansa AI involving the acquisition of Miimansa's clinical entity modeling tools based on large language models and generative AI. The partnership aims to accelerate the development of Emmes Group's Concord Gen AI platform and enhance its Veridix AI technology for automated text processing, protocol creation, and medical writing in clinical research. The deal enables Miimansa AI to apply its advanced AI techniques to real-world clinical trial environments, with the goal of making clinical research faster, more affordable, and more efficient.PR NewswireEmmes Group с Miimansa AI ускоряют внедрение генеративного ИИ в клинических исследованияхEmmes Group, a global contract research organization (CRO), announced a multi-year strategic partnership with Miimansa AI on July 23, 2024, involving the acquisition of Miimansa's clinical entity modeling tools based on large language models and generative AI. The technology will be integrated into Emmes' Veridix AI platform and the new Concord generative AI platform to accelerate processing of clinical data and automate text-to-text tasks such as protocol drafting and medical document writing. The partnership aims to reduce time and costs associated with manual data processing and analysis in clinical trials.